Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Updates on Clinical Trials in Systemic Lupus Erythematosus
Amir Sharabi
*
*
Corresponding author for this work
Clinical Microbiology and Immunology
Rabin Medical Center Israel
Research output
:
Contribution to journal
›
Review article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Updates on Clinical Trials in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Trials
100%
Systemic Lupus Erythematosus
100%
T Cell Activation
33%
B Cell Activation
33%
Therapeutic Effect
16%
B Cells
16%
Therapeutic Agents
16%
B-type
16%
Type I Interferon
16%
Target Molecule
16%
Bispecific Antibody
16%
Potential Therapeutics
16%
Binding Specificity
16%
Small Molecule Inhibitors
16%
CD40 Ligand (CD40L)
16%
Combination Treatment
16%
Low-dose IL-2
16%
Immunoregulation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Systemic Lupus Erythematosus
100%
Therapeutic Effect
16%
Interferon Type I
16%
Interleukin 2
16%
Bispecific Antibody
16%
CD40 Ligand
16%
Diseases
16%